Lipid levels in patients hospitalized with coronary artery disease: an analysis of 136,905 hospitalizations in Get With The Guidelines.

BACKGROUND Lipid levels among contemporary patients hospitalized with coronary artery disease (CAD) have not been well studied. This study aimed to analyze admission lipid levels in a broad contemporary population of patients hospitalized with CAD. METHODS The Get With The Guidelines database was analyzed for CAD hospitalizations from 2000 to 2006 with documented lipid levels in the first 24 hours of admission. Patients were divided into low-density lipoprotein cholesterol (LDL), high-density lipoprotein cholesterol (HDL), and triglyceride categories. Factors associated with LDL and HDL levels were assessed along with temporal trends. RESULTS Of 231,986 hospitalizations from 541 hospitals, admission lipid levels were documented in 136,905 (59.0%). Mean lipid levels were LDL 104.9 +/- 39.8, HDL 39.7 +/- 13.2, and triglyceride 161 +/- 128 mg/dL. Low-density lipoprotein cholesterol <70 mg/dL was observed in 17.6% and ideal levels (LDL <70 with HDL > or =60 mg/dL) in only 1.4%. High-density lipoprotein cholesterol was <40 mg/dL in 54.6% of patients. Before admission, only 28,944 (21.1%) patients were receiving lipid-lowering medications. Predictors for higher LDL included female gender, no diabetes, history of hyperlipidemia, no prior lipid-lowering medications, and presenting with acute coronary syndrome. Both LDL and HDL levels declined over time (P < .0001). CONCLUSIONS In a large cohort of patients hospitalized with CAD, almost half have admission LDL levels <100 mg/dL. More than half the patients have admission HDL levels <40 mg/dL, whereas <10% have HDL > or =60 mg/dL. These findings may provide further support for recent guideline revisions with even lower LDL goals and for developing effective treatments to raise HDL.

[1]  P. Sorlie,et al.  Trends in serum lipids and lipoproteins of adults, 1960-2002. , 2005, JAMA.

[2]  H. Liebich,et al.  Upregulation of cholesterol synthesis after acute myocardial infarction--is cholesterol a positive acute phase reactant? , 1999, Atherosclerosis.

[3]  S. Yusuf MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20536 high-risk individuals: a randomised placebo-controlled trial. Commentary , 2002 .

[4]  G. Mills,et al.  Influence of myocardial infarction on plasma-lipoprotein concentration. , 1959, Lancet.

[5]  W. Howard Trends in Serum Lipids and Lipoproteins of Adults, 1960–2002Carroll MD, Lacher DA, Sorlie PD, et al (Centers for Disease Control and Prevention, Hyattsville, Md; NIH, Bethesda, Md; Univ of Texas, Dallas) JAMA 294:1773–1781, 2005§ , 2006 .

[6]  N. Unwin,et al.  Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) Detection, Evaluation, and Treatment of High Blood Cholesterol Education Program (NCEP) Expert Panel on Executive Summary of the Third Report of the National , 2009 .

[7]  S. Grundy,et al.  National Cholesterol Education Program Third Report of the National Cholesterol Education Program ( NCEP ) Expert Panel on Detection , Evaluation , and Treatment of High Blood Cholesterol in Adults ( Adult Treatment Panel III ) Final Report , 2022 .

[8]  W. Castelli,et al.  Cholesterol and lipids in the risk of coronary artery disease--the Framingham Heart Study. , 1988, The Canadian journal of cardiology.

[9]  Neil J Stone,et al.  Implications of Recent Clinical Trials for the National Cholesterol Education Program Adult Treatment Panel III Guidelines , 2004, Circulation.

[10]  AndrewJ. S. Coats MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20 536 high-risk individuals: a randomised placebocontrolled trial , 2002, The Lancet.

[11]  J. Mckenney,et al.  Results of the National Cholesterol Education (NCEP) Program Evaluation ProjecT Utilizing Novel E-Technology (NEPTUNE) II survey and implications for treatment under the recent NCEP Writing Group recommendations. , 2005, The American journal of cardiology.

[12]  K. Flegal,et al.  Secular trends in cardiovascular disease risk factors according to body mass index in US adults. , 2005, JAMA.

[13]  J. Loscalzo,et al.  Lipid levels after acute coronary syndromes. , 2008, Journal of the American College of Cardiology.

[14]  H. Minuk,et al.  Metabolic syndrome. , 2005, Journal of insurance medicine.

[15]  S. Feasson,et al.  MRC/BHF heart protection study of cholesterol lowering with simvastatin in 20536 high-risk individuals : a randomised placebo-controlled trial. , 2008 .

[16]  J. Mckenney,et al.  National Cholesterol Education Program Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) , 2002 .

[17]  Thomas Weber,et al.  Intensive versus moderate lipid lowering with statins after acute coronary syndromes. , 2004, The New England journal of medicine.

[18]  T. Pearson,et al.  The lipid treatment assessment project (L-TAP): a multicenter survey to evaluate the percentages of dyslipidemic patients receiving lipid-lowering therapy and achieving low-density lipoprotein cholesterol goals. , 2000, Archives of internal medicine.

[19]  K. Watson,et al.  High-density lipoprotein function recent advances. , 2005, Journal of the American College of Cardiology.

[20]  R. Gliklich,et al.  Get with the guidelines for cardiovascular secondary prevention: pilot results. , 2004, Archives of internal medicine.